Navigation Links
Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents
Date:5/15/2008

e, effective and safe," said Tan. "This data might set the stage for a wider use of the pro-healing stent in patients with AMI."

Patients Who Could Not Tolerate Dual-Antiplatelet Therapy

Michael Kutryk, M.D., Ph.D., of St. Michael's Hospital in Toronto discussed the results of a compassionate-use study that enrolled 14 patients who could not tolerate dual-antiplatelet therapy or for whom the therapy was contraindicated. The study results show no thrombotic events at 17-month median follow-up.

"The implantation of a Genous stent should be considered first-line therapy in patients for whom dual-antiplatelet therapy is not an option," said Kutryk. "The Genous technology is critically important to this patient population for which there are limited treatments. In these cases, Genous might be the only lifesaving option."

Single-Center Registry of High-Risk Patients

Germano Di Sciascio, M.D., professor and chairman of cardiology at Campus Biomedico, University of Rome, discussed the results of a study involving 78 high-risk patients, 33% of whom were diabetic. In the study, 16% of the patients received multiple stents, and 56% of the lesions treated were type B2/C. The majority of patients received clopidogrel for two months. The results at 14-month follow-up show:

-- A TLR rate of only 4%

-- An event-free survival rate of 84%

-- No thrombotic events

-- A comparable MACE rate to the Taxus VI registry at nine months

"Given the current DES debate with the need for prolonged anti-aggregation, we believe this study demonstrated that Genous is a new armamentarium for PCI," said Di Sciascio.

Commenting on the functional importance of endothelial progenitor cells (EPCs) for accelerated natural healing, Jonathan Hill, M.D., of King's College, London, said, "Interventional cardiologists are taking notice of the critical role of EPCs in the vascular healing process. The Genous EPC capture technology is
'/>"/>

SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- Siemens Healthcare today announced a ... to help healthcare providers pursue ... within the HITECH provision of the American ... Featuring zero-percent interest terms for qualified customers, ... payments associated with their technology investment while ...
(Date:12/16/2009)... Virginia, December 16 Biovista Inc.,today announced ... Presentation Award,in Healthcare, at the 2009 New England ... The award, which recognizes cutting edge private companies,driving ... who competed with,over 50 other privately held companies ... Technology, Life Sciences and Clean-tech sectors. , ...
(Date:12/16/2009)... Avantium announced the,appointment of Gunnar Staaf as ... Staaf previously worked at Serentis Ltd, Astellas ... a range of commercial and executive,positions. The ... plan to,spin-out its pharmaceutical business. The company ... on its offering of proprietary,crystallization services and ...
Breaking Medicine Technology:Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 2Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 3Siemens Unveils Flexible Financing Solutions to Help Providers Achieve Meaningful Use 4Biovista Inc. Named Top Innovator in Life Sciences 2Avantium Appoints Gunnar Staaf as CEO Pharma 2Accuray Ranked 155th Fastest Growing Company in North America on Deloittes 2009 Technology Fast 500 28TM 29 5614 1Accuray Ranked 155th Fastest Growing Company in North America on Deloittes 2009 Technology Fast 500 28TM 29 5614 2Accuray Ranked 155th Fastest Growing Company in North America on Deloittes 2009 Technology Fast 500 28TM 29 5614 3Health information exchange conquers new frontier 3A Emergency medical services 59834 1Health information exchange conquers new frontier 3A Emergency medical services 59834 2Just published 3A Doctor of the Heart 3A My Life in Medicine by Isadore Rosenfeld M D 10438 1Just published 3A Doctor of the Heart 3A My Life in Medicine by Isadore Rosenfeld M D 10438 2
(Date:12/17/2009)... report offers a revealing portrait of the nearly one-in-three American adults ... ... VA (PRWEB) December 17, 2009 -- The National Alliance on Mental ... 2009 , which offers a revealing portrait of the nearly one-in-three ... study is based on interviews with 1,480 caregivers chosen at random ...
(Date:12/17/2009)... Stress Reduction Therapy or NSRTSM is found very effective in ... as allergies, asthma, migraines, chronic fatigue and a wide array ... country are using this holistic therapy including over 50 branded ... ... Allentown, PA (Vocus) December 16, 2009 -- BioVeda Health ...
(Date:12/16/2009)... Calif., Dec. 17 If proposed health ... standards in the employer-based insurance system. Approximately 18.4 ... age of 65 rely upon employer-based insurance for ... and Senate versions of reform legislation entail specific ... majority of employees work for firms that currently ...
(Date:12/16/2009)... 16 New Enterprise Associates, Inc. (NEA), ... that one of its portfolio companies, Acclarent, Inc., ... acquired by Ethicon, Inc., a Johnson & Johnson ... million (net of estimated cash on hand at ... to designing, developing and commercializing devices that address ...
(Date:12/16/2009)... Allscripts (Nasdaq: MDRX ) announced ... for the three and six months ended November ... Monday, January 11, 2010. Allscripts management will host ... company,s earnings and other information at 8:30 AM ... http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, Allscripts fiscal second ...
Breaking Medicine News(10 mins):Health News:NAMI Applauds New Report on Caregiving 2Health News:NAMI Applauds New Report on Caregiving 3Health News:BioVeda Health and Wellness Center of Allentown, PA Announces Its Grand Opening 2Health News:BioVeda Health and Wellness Center of Allentown, PA Announces Its Grand Opening 3Health News:BioVeda Health and Wellness Center of Allentown, PA Announces Its Grand Opening 4Health News:BioVeda Health and Wellness Center of Allentown, PA Announces Its Grand Opening 5Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 2Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 3Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4
... High-Value Jobs For Commonwealth, HARRISBURG, Pa., Feb. ... better able to put promising Pennsylvania,pharmaceuticals, biotech, medical ... for growth, Governor Edward G. Rendell said, with ... sciences industry remains one of the most dynamic ...
... Feb. 7 Assurant, Inc. ("Assurant"),(NYSE: AIZ ... products and services, announced today that its president,and ... to present at,the Merrill Lynch Insurance Investors Conference ... Access to Mr. Pollock,s presentation will be available ...
... Systems Continues Its Thought Leadership Series with a Discussion ... Dr. Kevin Fickenscher and Dr. Suzanne Delbanco, PLANO, ... to be a major concern for leaders in today,s,Healthcare ... World, Dr.,Kevin Fickenscher, Chief Medical Officer & Executive Vice ...
... study to assess the adverse effects of anti-retroviral drugs,shows ... risk of heart attack/the formation of blood clots in,the ... developing a,heart attack increases by 49%, with Abacavir; the ... patients with a high,underlying cardiovascular risk. The research findings ...
... is available in French and German . ... it lifted off from the Kennedy Space Center in Cape ... to Earth orbit, Columbus is in the expert hands of ... European astronaut corps: Lopold Eyharts of France and Hans Schlegel ...
... Netherlands February 7, 2008 A seemingly random ... death in adults with no previous symptoms may not ... in the Netherlands discovered that many people with congenital ... attacks by identifying and treating patients at risk. They ...
Other Medicine News:Health News:Pennsylvania Gov. Rendell: $10 Million Partnership With Harrisburg Venture Capital Firm Boosts PA's Life Sciences Industry 2Health News:Healthcare Tech and the World: Podcast Examines The Challenges & Opportunities for Change in the Healthcare Industry 2Health News:HIV drugs, Abacavir and Didanosine increase the risk of heart attack 2Health News:Europe's Columbus laboratory leaves Earth 2Health News:Europe's Columbus laboratory leaves Earth 3Health News:Europe's Columbus laboratory leaves Earth 4Health News:Europe's Columbus laboratory leaves Earth 5
View Mex-2 is designed for out-patient surgery, hospital rounds and house calls....
The ICP-Monitor for intraventricular, intraparenchymal and epidural measurement of intracranial pressure and for measuring cerebral perfusion pressure and compliance....
... ICP Monitoring System provides ... intracranial pressure at the ... levels. The information is ... through a hydrostatic column ...
Penfield Dissector #3...
Medicine Products: